SAT 3247
Alternative Names: SAT-3247Latest Information Update: 12 Dec 2025
At a glance
- Originator Satellos Bioscience
- Class Small molecules
- Mechanism of Action Adaptor-associated kinase 1 inhibitors
-
Orphan Drug Status
Yes - Duchenne muscular dystrophy
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Duchenne muscular dystrophy
- Preclinical Facioscapulohumeral muscular dystrophy; Muscle injury
Most Recent Events
- 09 Dec 2025 Human Research Ethics Committee (HREC) accepted the Therapeutic Goods Administration’s (TGA’s) Clinical Trial Notification (CTN) scheme for regulatory authorization of SAT 3247 in Duchenne muscular dystrophy
- 09 Dec 2025 The Medicine and Healthcare products Regulatory Agency (MHRA) granted authorization to Clinical Trial Application (CTA) for SAT 3247 in Duchenne muscular dystrophy
- 09 Dec 2025 The Medicines and Medical Devices Agency of Serbia (ALIMS) approved CTA for SAT 3247 in Duchenne muscular dystrophy